Does the media prefer IMNM or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Immunome. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 6 mentions for Immunome. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Immunome's score of 1.45 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MDGL or IMNM?

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Immunome. MarketBeat recorded 14 mentions for Madrigal Pharmaceuticals and 6 mentions for Immunome. Madrigal Pharmaceuticals' average media sentiment score of 1.59 beat Immunome's score of 1.45 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or IMNM?

In the previous week, Halozyme Therapeutics had 19 more articles in the media than Immunome. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 6 mentions for Immunome. Immunome's average media sentiment score of 1.45 beat Halozyme Therapeutics' score of 1.32 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 20 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABVX or IMNM?

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Immunome $6.94M 451.21 -$212.39M -$2.53 N/A

Is ABVX or IMNM more profitable?

Immunome's return on equity of -50.56% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Immunome N/A -50.56% -46.93%

Does the media favor ABVX or IMNM?

In the previous week, Immunome had 2 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Immunome and 4 mentions for Abivax. Immunome's average media sentiment score of 1.45 beat Abivax's score of 1.24 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMNM or PRAX more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Praxis Precision Medicines N/A -34.15% -32.42%

Does the media prefer IMNM or PRAX?

In the previous week, Immunome had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Immunome and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Immunome's score of 1.45 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immunome (IMNM) Competitors

$27.57 -1.30 (-4.50%)

As of 08/28/2026 04:00 PM Eastern

Compare

IMNM vs. ARWR, MDGL, HALO, ABVX, and PRAX

Should you buy Immunome stock or one of its competitors? Immunome's main competitors and comparable companies include Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Abivax (ABVX), and Praxis Precision Medicines (PRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunome compare to Arrowhead Pharmaceuticals?

Immunome (NASDAQ:IMNM) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Immunome has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Immunome's return on equity of -50.56% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Immunome. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	451.21	-$212.39M	-$2.53	N/A
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A

Immunome presently has a consensus target price of $34.64, suggesting a potential upside of 25.63%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, suggesting a potential upside of 14.63%. Given Immunome's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunome is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Immunome. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 6 mentions for Immunome. Arrowhead Pharmaceuticals' average media sentiment score of 1.52 beat Immunome's score of 1.45 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Immunome beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Immunome compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Immunome has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Immunome's return on equity of -50.56% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Immunome	N/A	-50.56%	-46.93%

Madrigal Pharmaceuticals currently has a consensus price target of $699.64, suggesting a potential upside of 31.08%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 25.63%. Given Madrigal Pharmaceuticals' higher probable upside, equities research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.87	-$288.28M	-$12.89	N/A
Immunome	$6.94M	451.21	-$212.39M	-$2.53	N/A

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Immunome. MarketBeat recorded 14 mentions for Madrigal Pharmaceuticals and 6 mentions for Immunome. Madrigal Pharmaceuticals' average media sentiment score of 1.59 beat Immunome's score of 1.45 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market. Comparatively, Immunome has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Summary

Madrigal Pharmaceuticals and Immunome tied by winning 8 of the 16 factors compared between the two stocks.

How does Immunome compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Halozyme Therapeutics had 19 more articles in the media than Immunome. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 6 mentions for Immunome. Immunome's average media sentiment score of 1.45 beat Halozyme Therapeutics' score of 1.32 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	20 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 13.43%. Immunome has a consensus target price of $34.64, suggesting a potential upside of 25.63%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Halozyme Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.19	$316.89M	$3.35	31.45
Immunome	$6.94M	451.21	-$212.39M	-$2.53	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Immunome's net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Immunome	N/A	-50.56%	-46.93%

Halozyme Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Immunome has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Immunome on 9 of the 16 factors compared between the two stocks.

How does Immunome compare to Abivax?

Abivax (NASDAQ:ABVX) and Immunome (NASDAQ:IMNM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Immunome	$6.94M	451.21	-$212.39M	-$2.53	N/A

In the previous week, Immunome had 2 more articles in the media than Abivax. MarketBeat recorded 6 mentions for Immunome and 4 mentions for Abivax. Immunome's average media sentiment score of 1.45 beat Abivax's score of 1.24 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunome's return on equity of -50.56% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Immunome	N/A	-50.56%	-46.93%

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 38.07%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 25.63%. Given Abivax's higher possible upside, research analysts clearly believe Abivax is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Immunome beats Abivax on 11 of the 14 factors compared between the two stocks.

How does Immunome compare to Praxis Precision Medicines?

Immunome (NASDAQ:IMNM) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Immunome had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Immunome and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Immunome's score of 1.45 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immunome currently has a consensus target price of $34.64, indicating a potential upside of 25.63%. Praxis Precision Medicines has a consensus target price of $585.95, indicating a potential upside of 69.96%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

Immunome has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market.

Immunome has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	451.21	-$212.39M	-$2.53	N/A
Praxis Precision Medicines	$8.55M	1,125.78	-$303.27M	-$12.93	N/A

Praxis Precision Medicines' return on equity of -34.15% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Summary

Praxis Precision Medicines beats Immunome on 11 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.28B	$4.01B	$7.23B	$12.94B
Dividend Yield	N/A	3.60%	2.54%	11.02%
P/E Ratio	-10.90	11.68	273.45	25.45
Price / Sales	451.21	1,348.86	621.81	95.39
Price / Cash	N/A	110.59	79.29	54.21
Price / Book	5.97	16.53	12.97	6.14
Net Income	-$212.39M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-3.33%	-0.30%	0.13%	-0.80%
1 Month Performance	19.30%	11.84%	8.37%	5.56%
1 Year Performance	189.91%	55.46%	24.55%	15.57%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.0594 of 5 stars	$27.57 -4.5%	$34.64 +25.6%	+178.5%	$3.28B	$6.94M	N/A	40	Positive News
ARWR Arrowhead Pharmaceuticals	2.5326 of 5 stars	$87.17 -1.7%	$97.33 +11.7%	+280.1%	$12.30B	$829.45M	N/A	400	Positive News
MDGL Madrigal Pharmaceuticals	3.5576 of 5 stars	$527.85 +0.6%	$689.93 +30.7%	+22.1%	$12.23B	$958.40M	N/A	90	Positive News
HALO Halozyme Therapeutics	3.8721 of 5 stars	$103.48 +0.5%	$91.20 -11.9%	+44.7%	$11.78B	$1.40B	30.97	390	News Coverage Positive News
ABVX Abivax	2.5238 of 5 stars	$119.59 -0.9%	$156.50 +30.9%	+38.8%	$10.45B	N/A	N/A	61	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. ARWR, MDGL, HALO, ABVX, and PRAX

How does Immunome compare to Arrowhead Pharmaceuticals?

Summary

How does Immunome compare to Madrigal Pharmaceuticals?

Summary

How does Immunome compare to Halozyme Therapeutics?

Summary

How does Immunome compare to Abivax?

Summary

How does Immunome compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. ARWR, MDGL, HALO, ABVX, and PRAX

How does Immunome compare to Arrowhead Pharmaceuticals?

Is IMNM or ARWR more profitable?

Which has more risk and volatility, IMNM or ARWR?

Do insiders and institutionals hold more shares of IMNM or ARWR?

Which has stronger valuation and earnings, IMNM or ARWR?

Do analysts recommend IMNM or ARWR?

Does the media prefer IMNM or ARWR?

Summary

How does Immunome compare to Madrigal Pharmaceuticals?

Is MDGL or IMNM more profitable?

Do analysts recommend MDGL or IMNM?

Which has better earnings & valuation, MDGL or IMNM?

Does the media prefer MDGL or IMNM?

Do insiders & institutionals hold more shares of MDGL or IMNM?

Which has more volatility and risk, MDGL or IMNM?

Summary

How does Immunome compare to Halozyme Therapeutics?

Does the media favor HALO or IMNM?

Do analysts recommend HALO or IMNM?

Which has higher earnings and valuation, HALO or IMNM?

Is HALO or IMNM more profitable?

Which has more risk & volatility, HALO or IMNM?

Do institutionals and insiders hold more shares of HALO or IMNM?

Summary

How does Immunome compare to Abivax?

Which has preferable valuation and earnings, ABVX or IMNM?

Does the media favor ABVX or IMNM?

Which has more risk and volatility, ABVX or IMNM?

Do institutionals & insiders hold more shares of ABVX or IMNM?

Is ABVX or IMNM more profitable?

Do analysts recommend ABVX or IMNM?

Summary

How does Immunome compare to Praxis Precision Medicines?

Do insiders & institutionals believe in IMNM or PRAX?

Does the media prefer IMNM or PRAX?

Do analysts recommend IMNM or PRAX?

Which has more volatility and risk, IMNM or PRAX?

Which has higher valuation & earnings, IMNM or PRAX?

Is IMNM or PRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools